• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    1,1 min -biphenyl-2-yl alkylamine derivatives of formula (I): <CHEM> wherein: X is hydrogen or a halo substituent at any position in the phenyl ring; R<1> is hydrogen, hydroxy, C IDENTICAL N, CONR<5>R<6>, or CO2R<8> where R<5>, R<6>, R<8> independently represent hydrogen or alkyl; R<2> is hydrogen or alkyl; Z is -(CH2)n- or -CH2@@CH2-; where n is an integer of from 2 to 4; R<3> and R<4> independently are hydrogen, C1-6 alkyl, CH2C2-5 alkenyl, phenyl C1-3 alkyl, or taken together with the adjacent nitrogen atom form a heterocyclic group or a pharmaceutically-acceptable salt thereof. The compounds are prepared by the usual methods for analogous compounds. They have been found to be effective in the treatment of cardiac arrhythmias. Pharmaceutical formulations have been prepared.
    公开号:SU940645A3
    申请号:SU802892804
    申请日:1980-03-12
    公开日:1982-06-30
    发明作者:Брайант Лейсфилд Вильям；Ли Саймонд Ричард
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    To a stirred solution of 3.5 g of sodium amide in 250 ml of dry toluene, a solution of 16.7 g of (1,1 -biphenyl-2-yl) acetonitrile in 200 ml of toluene was added dropwise over 30 minutes. The reaction mixture is heated to reflux temperature and stirred for 3 hours after the addition of the nitrile is complete. The reaction mixture is then cooled to room temperature, and a solution of a 1 ml g of M, M-dimethyl-3-chloropropylamine in 200 ml of dry toluene is added dropwise to the stirred solution over a period of 1 hour. After the addition is complete, the reaction mixture is heated to reflux temperature and stirring is continued for 16 hours. After cooling the reaction mixture to room temperature, it is added to 500 ml of ice-cold water. The product is extracted from the aqueous mixture in diethyl ether, the ether extracts are combined and washed with water, and then extracted several times with 6N. hydrochloric acid solution. The acid extracts are combined, washed with fresh diethyl ether, and then basified with 10% hydroxide solution. The alkaline solution is extracted with fresh diethyl ether, the ether extracts are combined, washed with water and dried. After removing the solvent by evaporation under reduced pressure and distilling the resulting product, 11.3 g of N, N-dimethyl-4-cyano- (1,1-biphenyl -2-yl) -butylamine are obtained; bp 157-1b2 ° C at 0.5 mm Hg Found, C 81, H 7.71; N 9.89 C gHrtnNn Calculated: C 81.97; H 7.97) N 10.06. 2-3. In accordance with Example 1, the following cyanoalkylamines are obtained: N, M-diisopropyl - -cyano- (1,1-biphenyl-2-yl) -butylamine. T, kip. 75 185 ° C at 0.3 mm Hg M ZZ. M-Benzyl-M-isopropyl-4-cyano- (1,1-biphenyl-2-yl) -butylamine. Bp 195-20 ° C at 0.1 mm Hg M + 382, P-p and meer. N, M-Dimethyl - + - aminocarbonyl-4- (1,1-biphenyl-2-yl-butylamine. 54 A solution of 2.4 g of N, N-dimethyl- -cyano- (1,1-biphenyl-2-yl a) -butylamine in 20 ml of concentrated sulfuric acid containing 5 ml of water is heated on a steam bath for 4 hours. The reaction mixture is then cooled to 5 ° C and alkalinized by adding 10% sodium hydroxide solution. The alkaline aqueous solution is extracted several times with diethyl ether. The ether extracts are combined, washed with water and dried. After evaporating the solvent under reduced pressure, a solid forms, which, after recrystallization from benzene and the Skelli-E solvent, gives 600 mg of M, M-dimethyl-1-aminocarbonyl- (1,1-biphenyl-2-yl) -butylamine, mp 108PO C., C 76.70; n 7, Found, 9, 2i Calculated,%: C 75.99; H 8.1 b; 9.55-6. In accordance with Example 4, the following amides result in acid hydrolysis of the corresponding nitriles: N, N-diisopropyl- 4-aminocarbonyl-y- (1,1-biphenyl-2-yl) -butylamine, mp: 70-72 ° C. Found: C 78.08; H 8.89; N 7,7t Calculated,%: C 78, ST; H 9.15; N 7.95 H-Benzyl-L-isopropyl-3 aminocarbonyl 3 (1, l-biffeyl-2-yl) -butylamine. Example 7. M, M-Dimethyl-β-hydroxycarbonyl- - (1,1-biphenyl-2-yl) -butylamine. A solution of 6.0 g of S, M-dimethyl-cyano-td, -biphenyl-2-yl) -butylamine in b5 ml of 90% sulfuric acid solution is heated on a steam bath for 8 hours. After cooling the reaction mixture to 5 ° C and alkalizing it by adding a 0% sodium hydroxide solution, the product is extracted from it in diethyl ether. The ether extracts are washed with water and dried. An excess amount of hydrogen chloride is bubbled through the ether solution, and a precipitate is formed, which is separated by filtration. As a result of the crystallization of the precipitate from ethanol, 2.9 g of S, M-dimethyl-α-hydroxycarbonyl- (1,1-biphenyl-2-yl) -butylaminium chloride are formed. Found: C 68.18; H 7.19; N, 39; O 10.00, (Xi C 68.35; H 7.25; Calculated: N, 20; O 9.58 Example 8. K-Isopropyl-5-aminocarbonyl-5 (1,1-biphenyl-2-yl ) -pentylamine, hydrochloride. 0) 5 Cyano-5- (1, 1-biphenyl-2-yl) -pentyl chloride. 1,1-Biphenyl-2-yl acetonitrile (19.3 g; 0.1 mol) is heated together with 1-bromo-chlorobutane (18.1 g; 0.11 mol) in the presence of sodium amide (4.3 g 0.11 mol) under nitrogen using dry toluene (500 ml) as a solvent, resulting in the desired product; m.p. 141-65 C / O, 6 mm, yield 1b, 5 g. C) H-Isopropyl-5-cyano-5- (1,1-biphenyl-2-yl) -pentylamine, hydrochloride. 5-Cyano-5- (1,1-biphenyl-2-yl) -pentyl chloride (13.7 g) is reacted with isopropylamine (100 ml) in an autoclave with potassium iodide (2 g) overnight. The resulting new base is converted to the salt of chlorine hydrate; m.p. 1 3-5С (recrystallized recrystallized EtOH / EtiO); yield i, 9 g c) The nitrile obtained in (d) is heated together with a 90% solution of sulfuric acid (20.0 g), resulting in the formation of an aminocarbonyl derivative, which is converted to the hydrochloride, i.e. N-isopropyl-5-aminocarbonyl-5- (1,1-biphenyl-2-yl) -pentylamine, hydrochloride so pl. 215-217 ° C (EtOH / Et, j, 0); yield 3.7 g. Example 9- Composition for dental use of the composition, L-Isopropyl-α-oxy-k- (, -biphenyl-2-yl) -butylamine chloride 25 Starch200 Sucrose275 The above ingredients are thoroughly mixed with suitable lubricants , and 19 S tablets are made from the resulting mixture. Example 10. Composition for internal use of the composition, mg: N, H-Diethyl - + - aminocarbonyl-4- (5-fluoro-1, 1-biphenyl-2-yl) butylamine chloride 250 Isotonic saline solution 500 10% aqueous glucose solution 500 The above ingredients are mixed, resulting in about an infusion solution is developed. The proposed biphenylylalkylamines are used as drugs for the treatment of cardiac arrhythmias. Experimental data were obtained on dogs, which artificially cause cardiac arrhythmia. In a general experiment, one or more courtyards of either sex are anesthetized using pentobarItalio sodium. A ButterFly-type needle is inserted into the dog's radial vein and a sufficient amount of a buibine that stimulates cardiac arrhythmia is fed into the vein of the dog, and the test compound is also injected into the dog through the same needle. During the experiment, each dog is continuously subjected to electrocardiographic examination. After the artificially induced cardiac arrhythmia continues for 30 minutes, compound (1) is introduced into the vein through a Butterfly-needle needle, the rate of administration is 200 mg / kg dog weight per minute. If cardiac arrhythmias do not stop and normal heart activity is not restored within 10 minutes after administration of the test compound (this fact is established by monitoring the electrocardiogram), the rate of administration of the test compound is increased to 500 mg / kg per minute. After the first signs of weakening of the cardiac arrhythmia are noticed, the administration of the test compound is generally continued until the dog is given twice the amount of this compound compared to the amount that causes the first signs of weakening of the cardiac arrhythmia. After the introduction of this amount of test compound is completed, the dog's heart activity is examined by means of an electrocardiogram for such a time to ensure that the dog's normal heart activity is restored completely S or for a maximum of 2 hours after which the test is completed. The results of several tests are given in Table. 1 and 2. Table 1
    N ,, СН ,, Н СНпСНпСНо З З, CONHf
    Each compound listed in the table and its corresponding biological assessment are indicated by a letter of the Latin alphabet, which is located in the compound column. Most of the compounds are tested several times. The amount of boobybe that is needed to cause an arrhythmia is given in milligrams per kilogram of dog weight. The dose causing normalization of heart activity, as well as the total dose of the test compound, are given in milligrams per kilogram of animal weight. The time for normalization of heart activity is given in minutes.
    ks - y - s
    E B
    In general, the active ingredient is 1-50 wt. such drugs. Compounds (|) are used
    table 2
    parenterally, for example, in the form of liquid solutions or suspensions for injection, or optically in the form of solid compositions in tablet form or enclosed in a gelatin capsule. Pharmaceutically acceptable diluents and fillers that are generally used to make solid compositions include starch, glucose, lactose, gelatin, malt, rice flour, silica gel, hydroxyethylcellulose, magnesium carbonate, sodium benzoate, and appropriate carriers. . Carriers used in the preparation of liquid compositions include ethanol, brine, sterile water, glucose syrup, acacia syrup, peanut oil, wheat kernel oil, sorbitan trioleate, ethyl oleate, lecithin, and the like. Injectable formulations are prepared for parenteral administration by intramuscular, subcutaneous or, preferably, intravenous administration.
    权利要求:
    Claims (1)
    [1]
    The effective amount of the drug used to treat ser2 9E Ob + B pediatric arrhythmias strongly depends on the method of use, on whether the patient has a moment of use, an attack of cardiac arrhythmia, on the severity of the disease, and on other factors. If at the time of use of the drug the patient has an attack of cardiac arrhythmia, then in general a dose is applied that is sufficient to restore normal heart activity. The compound (|) is generally used for parenteral administration and administration by the intravenous route at a dose sufficient to restore normal heart activity. In addition, to maintain normal heart activity, the proposed compound is used either parenterally or orally. The dose of the active compound, which is generally used to restore normal cardiac activity, varies in the region of 0.1-50 mg / kg of animal weight. The dose that is used in this case when administered intravenously is 0.5–20 mg / kg. Therapy supported by normal heart activity consists in using the active compound (I) in doses of 0.1-35 mg / kg of animal weight. A tablet intended for oral use in order to maintain a normal heart rate or prophylactic treatment of a human may contain, for example, mg of biphenylyl-alkylamine in combination with a suitable carrier. Such tablets are taken 3 times a day to prevent attacks of cardiac arrhythmias. mule where R or from py where hydroy de and at cl. 1 O Claims of the invention for the preparation of 1,1enyl-2-yl-alkylamine derivatives of the total form (I) G -. R to X is hydrogen; R —CONHrj, COOH; -hydrogen, methyl; Z - (CH, j)% R - independently of each other hydrogen, methyl, isopropyl or benzyl, their salts, indicating that the nitrile of the general form I), X and Z - as stated above, are olized in an acidic medium, and the product is isolated in the free form of salt as a salt. Sources of information that are considered in the examination. Patent of the USSR No. 706022, C 07 C 102/08, 06.06.77.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP0371876A1|1990-06-06|Isoxazoles and isoxazolines with an anticonvulsive activity, and pharmaceutical compositions containing them
    CA1284329C|1991-05-21|[| oxy] ethanimidamides and [| oxy]-ethanimidic acid hydrazides,their derivatives and their salts
    EP0022118A1|1981-01-07|Derivatives of sulfonyl aniline, process for their preparation and their use in therapy
    LU80461A1|1980-05-07|QUINAZOLINE DERIVATIVES, THEIR PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
    LU87173A1|1988-11-17|PHARMACOLOGICALLY ACTIVE SUBSTITUTED BENZAMIDES
    RU2090553C1|1997-09-20|N-phenyl-2-cyano-3-hydroxycrotonic acid amide, method of its synthesis and drug showing antiinflammatory activity with respect to rheumatic disease, autoimmune disease or rejection response of recipient transplantable organ
    EP0248824A1|1987-12-16|Use of CIS-N-| benzene acetamide and Benzamide for the manufacture of anticonvulsants.
    SU1022656A3|1983-06-07|Method of producing derivatives of 9-aminoalkylfluorene or their salts
    SU940645A3|1982-06-30|Process for producing derivatives of 1,1&#39;-biphenyl-2-ylalkylamine
    US3000903A|1961-09-19|Phenylalkylhydrazines and use as psychotherapeutics
    SU1344245A3|1987-10-07|Versions of method of producing n-|-nъ-phenylurea or pharmacologically acceptable salts thereof
    US3682922A|1972-08-08|N-acyl-n-{8 |-alkyl{9 -1-adamantylmethylamines
    JP2003508381A|2003-03-04|Use of bissulfonamide for the manufacture of a medicament for preventing or treating hyperlipidemia
    US3467705A|1969-09-16|Neurotropic amides from n-substituted aminomethyl-nor-camphane and a procedure for their preparation
    US4897423A|1990-01-30|Dinitrobenzenesulfonamides
    US3910871A|1975-10-07|Novel glycylglycine amides
    US4223041A|1980-09-16|Urea derivatives to treat anxiety and aggressivity
    US3331845A|1967-07-18|1-substituted-4-substituted amino alkylene piperazines
    SU810080A3|1981-02-28|Method of preparing |dioxazocin derivatives or their acid-additive salts
    US4169106A|1979-09-25|Antiarrhythmic N,N&#39;-bis|amidines
    SU828965A3|1981-05-07|Method of preparing hexahydro-1,4-oxazepins or their salts
    FR2491470A1|1982-04-09|NOVEL CYCLOPROPYLMETHYL PIPERAZINES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
    IL43726A|1977-07-31|1-phenoxy-3-|ethylamino-2-propanol derivatives and pharmaceutical compositions containing them
    IE50228B1|1986-03-05|Nitrosourea derivatives,process for preparing them,and pharmaceutical compositions containing them
    US3308019A|1967-03-07|Alkyl-n-[alpha, alpha-dimethyl-beta-|-ethyl]-carbamates and compositions thereof
    同族专利:
    公开号 | 公开日
    PT70928A|1980-04-01|
    CA1144926A|1983-04-19|
    ZA801421B|1981-10-28|
    ES8105262A1|1981-05-16|
    EP0015776A1|1980-09-17|
    AT367395B|1982-06-25|
    EP0015776B1|1982-06-30|
    AU528060B2|1983-04-14|
    KR840000103B1|1984-02-11|
    ES489469A0|1981-05-16|
    ES8201528A1|1981-12-16|
    ES497206A0|1981-12-16|
    CH644094A5|1984-07-13|
    GB2046256B|1983-04-20|
    IT8020503D0|1980-03-11|
    DE3060611D1|1982-08-19|
    RO79906A|1982-10-11|
    ATA134580A|1981-11-15|
    PL222601A1|1981-01-30|
    SU1022655A3|1983-06-07|
    FI800736A|1980-09-13|
    ES8201525A1|1981-12-16|
    NZ193079A|1982-05-31|
    PL121662B1|1982-05-31|
    MX6219E|1984-12-21|
    ES8201526A1|1981-12-16|
    FR2451363A1|1980-10-10|
    ES497208A0|1981-12-16|
    ES497209A0|1981-12-16|
    BE882167A|1980-09-11|
    IE49552B1|1985-10-30|
    LU82237A1|1980-06-06|
    DK103480A|1980-09-13|
    ES8201529A1|1981-12-16|
    JPS55127347A|1980-10-02|
    IL59557D0|1980-06-30|
    AR228852A1|1983-04-29|
    IT1140773B|1986-10-10|
    GB2046256A|1980-11-12|
    IL59557A|1983-10-31|
    KR830001854A|1983-05-19|
    ES497207A0|1981-12-16|
    GR68036B|1981-10-27|
    AU5630280A|1980-09-18|
    IE800493L|1980-09-12|
    HU180334B|1983-02-28|
    CS215052B2|1982-07-30|
    ES497210A0|1981-12-16|
    FR2451363B1|1983-01-14|
    DD149664A5|1981-07-22|
    PH14749A|1981-11-20|
    ES8201527A1|1981-12-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    ES236010A1|1956-06-29|1957-12-16|Lab Pharmaceutica Dr C Janssen|A procedure for preparing new parasimpaticolytically active derivatives of alpas-defenil propane |
    US3433836A|1966-01-14|1969-03-18|Rexall Drug Chemical|Alpha-diaryl alpha,omega-alkylene glycol-dilower-alkylamines|
    GB1475314A|1973-11-02|1977-06-01|Cm Ind|Phenyl-propylamine derivatives|
    IL48319D0|1974-10-26|1975-12-31|Merck Patent Gmbh|Araliphatic nitrogen compounds and a process for their preparation|
    GB1523655A|1975-02-10|1978-09-06|Armour Pharma|4- butylamines and treatment of the animal organism therewith|KR100470454B1|2002-05-14|2005-02-05|대한민국|Auto-control feeder to provide feed of pigs|
    US20080139481A1|2004-06-17|2008-06-12|Dix Thomas A|Non-Natural Amino Acids|
    EP2511273B8|2011-04-15|2019-06-26|Hivih|Inhibitors of viral replication, their process of preparation and their therapeutical uses|
    EP2821104A1|2013-07-05|2015-01-07|Laboratoire Biodim|Inhibitors of viral replication, their process of preparation and their therapeutical uses|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US1953479A| true| 1979-03-12|1979-03-12|
    [返回顶部]